momelotinib

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
Fierce Pharma
Sun, 09/17/23 - 09:47 pm
GSK
FDA
Ojaara
momelotinib
myelofibrosis
FDA delays approval decision on GSK's $1.9B blood cancer bet
Fierce Biotech
Fri, 06/16/23 - 09:52 am
GSK
FDA
momelotinib
blood cancer
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Wed, 05/10/23 - 10:18 am
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
Fierce Biotech
Mon, 12/12/22 - 10:23 am
GSK
Sierra Oncology
momelotinib
myelofibrosis
ASH 2022
Was This Acquisition a Smart Move for GlaxoSmithKline?
Motley Fool
Sun, 05/15/22 - 11:10 pm
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Fierce Biotech
Fri, 06/28/19 - 12:28 pm
Sierra Oncology
myelofibrosis
Gilead Sciences
momelotinib
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Xconomy
Wed, 08/22/18 - 05:47 pm
Gilead Sciences
Sierrra Oncology
myelofibrosis
momelotinib
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Sat, 11/19/16 - 11:32 am
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis